By Timothy J. King, Ph.D., Vice President, Research Osteoarthritis (OA) is the most common form of arthritis, a chronic disease of aging. Effective and safe long-term treatment for most OA patients is not available, creating a large unmet medical need. The potential market for OA is very large, where it is estimated that more than 150 million middle class people globally suffer from OA. Symptomatic knee OA alone affects roughly 12% of persons 60 years…
By Timothy J. King, Ph.D., Vice President, Research Studies utilizing rodent models of diabetes, diabetic nephropathy and metabolic dysfunction have shown astaxanthin (ASTX) administration to significantly and positively alter diabetes-associated pathology including dysregulation of glucose levels and insulin sensitivity [1-5].
By Gilbert Rishton, Ph.D., Cardax Chief Science Officer I accepted my position at Cardax as a seasoned veteran of the pharmaceutical industry. And, while my industry experience was indeed marked with satisfying projects, and even a successful drug launch with my former colleagues at Amgen, my most profound impression of modern drug development is in its epic failures. Particularly, the industry has failed to deliver the innovative new drugs that were to address society’s most…
By David G. Watumull, Cardax President and CEO It is my distinct pleasure to welcome you to the first Cardax blog post. Our goal is to provide timely and interactive communication for investors and others interested in our Company. In addition to formal press releases and SEC filings we make available through other channels, we hope to offer personal perspective on several relevant areas, including the Company’s progress, capital markets, and relevant developments in the…
Cardax, Inc.
2800 Woodlawn Drive, #129
Honolulu, Hawaii 96822
Phone: (808) 457-1400
press@cardaxpharma.com
